WEKO3
アイテム
{"_buckets": {"deposit": "8d544efb-a556-4db2-ad1e-a4bed084a71d"}, "_deposit": {"created_by": 2, "id": "9102", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "9102"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00009102", "sets": ["11"]}, "author_link": ["36423", "36426", "36425", "36427", "36424", "36422", "36421"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-06-29", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "724", "bibliographicPageStart": "717", "bibliographicVolumeNumber": "22", "bibliographic_titles": [{"bibliographic_title": "Thyroid"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: We previously reported the partial effectiveness of imatinib (also known as STI571, Glivec, or Gleevec) on anaplastic thyroid cancer (ATC) cells. Imatinib is a selective tyrosine kinase inhibitor that has been used for various types of cancer treatments. Recently, several reports have demonstrated that imatinib enhanced the sensitivity of cancer cells to other anticancer drugs. In this study, therefore, we investigated whether imatinib enhances the antitumor activity of docetaxel in ATC cells. Methods: Two ATC cell lines, FRO and KTC-2, were treated with imatinib and/or docetaxel. Cell survival assay and flow cytometry for annexin V were used to assess the induction of apoptosis. Changes of pro- and antiapoptotic factors were determined by Western blot. Nuclear factor-κB (NF-κB) activity was measured by DNA-binding assay. Tumor growth was also investigated in vivo. Results: The combined treatment significantly enhanced apoptosis compared with single treatment. ATC cells themselves expressed high levels of antiapoptotic factors, X-linked inhibitor of apoptosis (XIAP), and survivin. The treatment with docetaxel alone further increased their expressions; however, the combined treatment blocked the inductions. Although imatinib alone had no effect on NF-κB background levels, combined treatment significantly suppressed the docetaxel-induced NF-κB activation. Further, the combined administration of the drugs also showed significantly greater inhibitory effect on tumor growth in mice xenograft model. Conclusions: Imatinib enhanced antitumor activity of docetaxel in ATC cells. Docetaxel seemed to induce both pro- and antiapoptotic signaling pathways in ATC cells, and imatinib blocked the antiapoptotic signal. Thus, docetaxel combined with imatinib emerges as an attractive strategy for the treatment of ATC.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Thyroid, 22(7), pp.717-724; 2012", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Mary Ann Liebert Inc."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1089/thy.2011.0380", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "This is a copy of an article published in the Thyroid © 2012 copyright Mary Ann Liebert, Inc.; Thyroid is available online at: http://online.liebertpub.com."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "10507256", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "15579077", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kim, EunSook"}], "nameIdentifiers": [{"nameIdentifier": "36421", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuse, Michiko"}], "nameIdentifiers": [{"nameIdentifier": "36422", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saenko, Vladimir"}], "nameIdentifiers": [{"nameIdentifier": "36423", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki, Keiji"}], "nameIdentifiers": [{"nameIdentifier": "36424", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohtsuru, Akira"}], "nameIdentifiers": [{"nameIdentifier": "36425", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mitsutake, Norisato"}], "nameIdentifiers": [{"nameIdentifier": "36426", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamashita, Shunichi"}], "nameIdentifiers": [{"nameIdentifier": "36427", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Thy22_717.pdf", "filesize": [{"value": "1.8 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1800000.0, "url": {"label": "Thy22_717.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/9102/files/Thy22_717.pdf"}, "version_id": "6b6a7812-e936-4fca-89d5-866ed0e424b9"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "caspase 3", "subitem_subject_scheme": "Other"}, {"subitem_subject": "docetaxel", "subitem_subject_scheme": "Other"}, {"subitem_subject": "I kappa B alpha", "subitem_subject_scheme": "Other"}, {"subitem_subject": "imatinib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "immunoglobulin enhancer binding protein", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lipocortin 5", "subitem_subject_scheme": "Other"}, {"subitem_subject": "nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase", "subitem_subject_scheme": "Other"}, {"subitem_subject": "survivin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "transcription factor RelA", "subitem_subject_scheme": "Other"}, {"subitem_subject": "X linked inhibitor of apoptosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "anaplastic thyroid cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "animal experiment", "subitem_subject_scheme": "Other"}, {"subitem_subject": "animal model", "subitem_subject_scheme": "Other"}, {"subitem_subject": "antineoplastic activity", "subitem_subject_scheme": "Other"}, {"subitem_subject": "apoptosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "article", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cancer inhibition", "subitem_subject_scheme": "Other"}, {"subitem_subject": "carcinoma cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cell count", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cell growth", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cell survival", "subitem_subject_scheme": "Other"}, {"subitem_subject": "controlled study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "DNA binding", "subitem_subject_scheme": "Other"}, {"subitem_subject": "flow cytometry", "subitem_subject_scheme": "Other"}, {"subitem_subject": "human", "subitem_subject_scheme": "Other"}, {"subitem_subject": "human cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "human tissue", "subitem_subject_scheme": "Other"}, {"subitem_subject": "in vivo study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "male", "subitem_subject_scheme": "Other"}, {"subitem_subject": "mouse", "subitem_subject_scheme": "Other"}, {"subitem_subject": "nonhuman", "subitem_subject_scheme": "Other"}, {"subitem_subject": "priority journal", "subitem_subject_scheme": "Other"}, {"subitem_subject": "protein cleavage", "subitem_subject_scheme": "Other"}, {"subitem_subject": "protein expression", "subitem_subject_scheme": "Other"}, {"subitem_subject": "signal transduction", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tumor growth", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tumor volume", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tumor xenograft", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Western blotting", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells"}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/29682", "pubdate": {"attribute_name": "公開日", "attribute_value": "2012-11-12"}, "publish_date": "2012-11-12", "publish_status": "0", "recid": "9102", "relation": {}, "relation_version_is_last": true, "title": ["Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells"], "weko_shared_id": -1}
Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells
http://hdl.handle.net/10069/29682
http://hdl.handle.net/10069/296829ede1340-92b3-42ea-a281-9a0b53b360e6
名前 / ファイル | ライセンス | アクション |
---|---|---|
Thy22_717.pdf (1.8 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2012-11-12 | |||||
タイトル | ||||||
タイトル | Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | caspase 3 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | docetaxel | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | I kappa B alpha | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | imatinib | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | immunoglobulin enhancer binding protein | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | lipocortin 5 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | survivin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | transcription factor RelA | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | X linked inhibitor of apoptosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | anaplastic thyroid cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | animal experiment | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | animal model | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | antineoplastic activity | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | apoptosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | article | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | cancer inhibition | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | carcinoma cell | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | cell count | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | cell growth | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | cell survival | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | controlled study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | DNA binding | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | flow cytometry | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | human | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | human cell | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | human tissue | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | in vivo study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | male | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | mouse | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | nonhuman | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | priority journal | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | protein cleavage | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | protein expression | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | signal transduction | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | tumor growth | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | tumor volume | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | tumor xenograft | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Western blotting | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kim, EunSook
× Kim, EunSook× Matsuse, Michiko× Saenko, Vladimir× Suzuki, Keiji× Ohtsuru, Akira× Mitsutake, Norisato× Yamashita, Shunichi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: We previously reported the partial effectiveness of imatinib (also known as STI571, Glivec, or Gleevec) on anaplastic thyroid cancer (ATC) cells. Imatinib is a selective tyrosine kinase inhibitor that has been used for various types of cancer treatments. Recently, several reports have demonstrated that imatinib enhanced the sensitivity of cancer cells to other anticancer drugs. In this study, therefore, we investigated whether imatinib enhances the antitumor activity of docetaxel in ATC cells. Methods: Two ATC cell lines, FRO and KTC-2, were treated with imatinib and/or docetaxel. Cell survival assay and flow cytometry for annexin V were used to assess the induction of apoptosis. Changes of pro- and antiapoptotic factors were determined by Western blot. Nuclear factor-κB (NF-κB) activity was measured by DNA-binding assay. Tumor growth was also investigated in vivo. Results: The combined treatment significantly enhanced apoptosis compared with single treatment. ATC cells themselves expressed high levels of antiapoptotic factors, X-linked inhibitor of apoptosis (XIAP), and survivin. The treatment with docetaxel alone further increased their expressions; however, the combined treatment blocked the inductions. Although imatinib alone had no effect on NF-κB background levels, combined treatment significantly suppressed the docetaxel-induced NF-κB activation. Further, the combined administration of the drugs also showed significantly greater inhibitory effect on tumor growth in mice xenograft model. Conclusions: Imatinib enhanced antitumor activity of docetaxel in ATC cells. Docetaxel seemed to induce both pro- and antiapoptotic signaling pathways in ATC cells, and imatinib blocked the antiapoptotic signal. Thus, docetaxel combined with imatinib emerges as an attractive strategy for the treatment of ATC. | |||||
書誌情報 |
Thyroid 巻 22, 号 7, p. 717-724, 発行日 2012-06-29 |
|||||
出版者 | ||||||
出版者 | Mary Ann Liebert Inc. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 10507256 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 15579077 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1089/thy.2011.0380 | |||||
権利 | ||||||
権利情報 | This is a copy of an article published in the Thyroid © 2012 copyright Mary Ann Liebert, Inc.; Thyroid is available online at: http://online.liebertpub.com. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Thyroid, 22(7), pp.717-724; 2012 |